Literature DB >> 6976235

The primary serological response to a single dose of adsorbed tetanus toxoid, high concentration type.

J G Breman, G G Wright, L Levine, W C Latham, K P Compaoré.   

Abstract

Single-dose immunization against tetanus was studied in 511 previously non-immunized residents of rural villages in Upper Volta. Males and females were equally represented and a wide age range was covered. A single dose of adsorbed tetanus toxoid containing 17.5 Lf units of toxoid and 3.86 mg of aluminium phosphate per 0.5 ml dose was used. Blood samples were taken 7 days, 2 months, and 12 months after immunization, and serum antitoxin titres were determined by neutralization titrations in mice. Adverse reactions were negligible. Only 2 participants gave evidence of prior immunization by developing detectable antitoxin titres after 7 days; they were eliminated from the study. After 12 months, 59% of the participants had antitoxin titres of >/=0.01 IU/ml, a titre usually considered protective. The mean titre and the proportion of those protected decreased substantially with increasing age; overall, females gave somewhat greater serological responses than males. Mean titre increased by 25% between 2 months and 1 year after immunization; the increase was greater in females than in males. In children under 6 years of age, 100% of females and 82% of males had protective titres after 1 year.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6976235      PMCID: PMC2396113     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  Single-dose antenatal tetanus immunisation.

Authors:  J P Stanfield; D Gall; P M Bracken
Journal:  Lancet       Date:  1973-02-03       Impact factor: 79.321

Review 2.  Host factors in the response to immunization.

Authors:  G Edsall; M A Belsey; D R LeBlanc; L Levine
Journal:  Prog Drug Res       Date:  1975

3.  The serological assessment of a tetanus toxoid field trial.

Authors:  K W Newell; D R Leblanc; G Edsall; L Levine; H Christensen; M H Montouri; N Ramirez
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

4.  International collaborative studies on potency assays of diphtheria and tetanus toxoids.

Authors:  J D Van Ramshorst; T K Sundaresan; A S Outschoorn
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

5.  [Antitetanus vaccination: preliminary results of a study in Africa].

Authors:  B Durand; A Turpin; E H Relyveld; J Carrie; D Robert; R Fontanges; M Rey
Journal:  Dev Biol Stand       Date:  1978

6.  The early primary immune response to absorbed tetanus toxoid in man: A study of the influence of antigen concentration, carrier concentration, and sequence of dosage on the rate, extent, and persistence of the immune response to one and to two doses of toxoid.

Authors:  R Maclennan; L Levine; K W Newell; G Edsall
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

  6 in total
  5 in total

1.  Control of neonatal tetanus.

Authors:  A M Galazka
Journal:  Indian J Pediatr       Date:  1985 Jul-Aug       Impact factor: 1.967

Review 2.  Tetanus in Ethiopia: unveiling the blight of an entirely vaccine-preventable disease.

Authors:  Yohannes Woubishet Woldeamanuel
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

Review 3.  Neonatal tetanus in the world today.

Authors:  J P Stanfield; A Galazka
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

4.  Duration of protective immunity conferred by maternal tetanus toxoid immunization: further evidence from Matlab, Bangladesh.

Authors:  M A Koenig; N C Roy; T McElrath; M Shahidullah; B Wojtyniak
Journal:  Am J Public Health       Date:  1998-06       Impact factor: 9.308

5.  The influence of malaria and gestation on the immune response to one and two doses of adsorbed tetanus toxoid in pregnancy.

Authors:  B J Brabin; J Nagel; A M Hagenaars; E Ruitenberg; A M van Tilborgh
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.